ALNY Sep 2024 210.000 call
| Previous close | 8.40 |
| Open | 8.27 |
| Bid | 7.00 |
| Ask | 10.20 |
| Strike | 210.00 |
| Expiry date | 2024-09-20 |
| Day's range | 8.27 - 8.40 |
| Contract range | N/A |
| Volume | |
| Open interest | 37 |
ZacksGear Up for Alnylam (ALNY) Q1 Earnings: Wall Street Estimates for Key Metrics
Beyond analysts' top -and-bottom-line estimates for Alnylam (ALNY), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.
PR NewswireMedison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia
Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies for patients in international markets, and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today a further expansion of their existing partnership in Central & Eastern Europe and Israel, to also include selected markets in LATAM and APAC and additional international markets.
ZacksAlnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
